This disclosure provides pro-drug antibodies which specifically bind to tissue factor pathway inhibitor (TFPI) only after exposure to proteases from the coagulation cascade. The pro-drug antibodies described are useful for treating bleeding disorders such as hemophilia. When used in such treatments, these pro-drug antibodies show increased half-life relative to other anti-TFPI antibodies, while mitigating the potential for side effects such as thrombosis.本發明提供僅在暴露於凝血級聯的蛋白酶之後才會特異地結合至組織因子路徑抑制劑(TFPI)的前藥抗體。所述前藥抗體可用於治療諸如血友病的出血障礙。當使用於此等治療時,這些前藥抗體相對於其他抗TFPI抗體顯示半衰期增加,同時減輕諸如血栓的副作用可能性。
